

PTO 892 DEAFCE 1994 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		SERIAL NUMBER 10/032,162		Art Unit 1648		Attachment to Paper Number 10	
NOTICE OF REFERENCES CITED							
		APPLICANTS : Binley, J. M., <i>et al.</i>					
U.S. PATENT DOCUMENTS							
*	DOCUMENT NUMBER	DATE	NAME(S)	CLASS	SUBCLASS	FILING DATE	
	5,474,914	12/12/95	Spaete, R.	435	69.1	07/29/92	
FOREIGN PATENT DOCUMENTS							
*	DOCUMENT NO.	DATE	COUNTRY	NAME			
*	OTHER REFERENCES (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
*	Farzan, M., <i>et al.</i> , 1998, "Stabilization of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers by Disulfide Bonds Introduced into the gp41 Glycoprotein Ectodomain", J. Virol. 72(9):7620-7625.						
	Haynes, B. F., <i>et al.</i> , 1996, "Update on the Issues of HIV Vaccine Development", Ann. Med. 28:39-41.						
	Burton, D. R., and J. P. Moore, 1998, "Why do we not have an HIV vaccine and how can we make one?", Nature Med. Vaccine Suppl. 4(5):495-498.						
	Letvin, N. L., 1998, "Progress in the Development of an HIV-1 Vaccine", Science 280:1875-1880.						
*	Binley, J. M., <i>et al.</i> , 2000, "A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure", J. Virol. 74(2):627-643.						
	Cao, J., <i>et al.</i> , 1993, "Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein", J. Virol. 67(5):2747-2755.						
	Maerz, A. L., <i>et al.</i> , 2001, "Functional Analysis of the Disulfide-Bonded Loop/Chain Reversal Region of Human Immunodeficiency Virus Type 1 gp41 Reveals a Critical Role in gp120-gp41 Association", J. Virol. 75(14):6635-6644.						

EXAMINER	DATE	* A COPY OF THIS REFERENCE IS NOT BEING FURNISHED WITH THIS OFFICE ACTION. (SEE MPEP SECTION 707.05(a).
Jeffrey S. Parkin, Ph.D.	12/12/03	PAGE 1 OF 1